Click on a study below to see more information:
Study Conclusions – 31 Jan 2008:
40% of subjects treated during acute infection (AI) or recent infection (RI) sustained a viral load <5,000 copies/mL after 24 weeks of treatment interruption. The final results of ACTG 371 suggest that there was no significant difference between those with AI and RI in their ability to be virally suppressed after treatment interruption. It was found that the level of the participants’ viral load before treatment may be related to the treatment outcome i.e. those with viral load <5,000 copies/mL before treatment were more likely, than others, to sustain viral load levels below 5,000 copies/mL after treatment interruption.
ACTG A5146 – Evaluating the Impact of Therapeutic Drug Monitoring on Virologic Response to a Salvage Regimen
Study Conclusions – 30 Jan 2008:
The A5146 study showed that, overall, participants with NIQs less than or equal to 1 did not benefit from increasing their dose of protease inhibitor, and did not have any more side effects, compared to participants that did not increase their protease inhibitor dose. Increased doses of protease inhibitors were well tolerated and there were no safety differences between the TDM and SOC arms.
However, some studies analyzing different groups of participants show that patients with less HIV that is less resistant to their protease inhibitor might do better if their dose of protease inhibitor were increased. Black and Hispanic patients also might do better on higher doses of protease inhibitors if their NIQ is less than or equal to 1. The A5146 study team is planning studies to see whether genetic changes could possibly explain the differences between white, black and Hispanic participants, by doing genetic testing on samples from participants who consented to genetic testing as part of the A5128 study.
ACTG A5164 – Antiretroviral Therapy for HIV-Infected Adults with Acute Opportunistic Infections: Immediate versus Deferred Treatment
Study Conclusions – 02 Feb 2008:
A5164 demonstrated that starting anti-HIV drugs while the treatment for an OI or BI is ongoing can be as safe as waiting to start anti-HIV drugs until the treatment for the OI or BI has been completed. The study results also suggest that the early start of anti-HIV drugs is associated with fewer deaths and new AIDS-related complications. The team therefore recommends that anti-HIV drugs be started as early as possible when a patient comes into care with an active AIDS-related OI or BI.
ACTG A5197 – Evaluation of the Antiretroviral Effect of Immunization with the MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals Who Interrupt Antiretroviral Drug Therapy
Study Conclusions – 30 Jan 2008:
The results from the vaccination and analytical treatment interruption (ATI) phases of A5197 suggest that the vaccine was safe and that there were no differences in the CD4 cell counts of the two groups of participants during the ATI. The results also suggest that there was a trend (although not significant) for participants who received the vaccine to have a lower viral load during the ATI than the participants who received the placebo. Thus, there was no evidence of harm from the vaccine and, if anything, there was a trend toward better viral control during the treatment interruption period.